TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01548105

Intervention type: OTHER
Intervention: Blood draw for the study participants
Description: These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels

Intervention type: OTHER
Intervention: Blood draw for the study participants
Description: These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels

Intervention type: OTHER
Intervention: Blood draw for the study participants
Description: These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels

Intervention type: OTHER
Intervention: Blood draw for the study participants
Description: These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels
Study: NCT02569190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkbot
Description: Robot assisted gait training
Study: NCT03909074

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 36-71 months old children-control EV71 vaccine.
Description: Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
Study: NCT04536727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit & Strong!
Description: The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list
Description: Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
Study: NCT03510117

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Mindfulness
Study: NCT03272919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1: Investigational INF
Description: INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2: standardized muscle stretching and strength
Description: subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
Study: NCT03909074

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-35 months old children-experimental EV71 vaccine.
Description: Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
Study: NCT02806752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
Study: NCT03923647

Intervention type: DEVICE
Intervention: Laparoscopy
Description: Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
Study: NCT01457937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon, Ribavirin, Boceprevir
Description: PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon, Ribavirin, Boceprevir
Description: PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)
Study: NCT03678571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Latrunculin A supplemented vitrification medium
Description: Vitrification of human oocyte in medium supplemented with Latrunculin A
Study: NCT03323398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2416
Description: mRNA encoding human OX40L

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2416
Description: mRNA encoding human OX40L

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PD-L1 inhibitor
Study: NCT03204682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
Study: NCT05076461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
Study: NCT02806752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal inject 0.5mg of Ranibizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal inject 0.5mg of Ranibizumab.
Study: NCT00344773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg tablet oral tablet once daily
Study: NCT01730183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow derived stem cells
Description: Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
Study: NCT02361710

Intervention type: PROCEDURE
Intervention: frozen embryo transfer
Description: comparison of groups according to their serum vitamin D levels on frozen embryo transfer day

Intervention type: PROCEDURE
Intervention: frozen embryo transfer
Description: comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
Study: NCT00500370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection (equivalent volume to active dose), twice a day
Study: NCT02905188

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLYCAR T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Study: NCT01437488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: * Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: 6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
Study: NCT03629184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
Study: NCT00742963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2
Study: NCT03406338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasciectomy
Description: Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
Study: NCT00437411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Self-Awareness workshop
Description: Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
Study: NCT02337192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO + water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study: NCT04453189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
Study: NCT01895738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WrapAround Care
Description: Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
Study: NCT00436943

Intervention type: DRUG
Intervention: nicotine replacement therapy and bupropion
Description: 3-6 months

Intervention type: BEHAVIORAL
Intervention: smoking cessation counseling and referrals
Description: Organizational counseling and referrals
Study: NCT02766244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG/SPY
Description: indocyanine green fluorescence imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Ointment
Description: Antibiotic ointment
Study: NCT00714259

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day x 3 days
Study: NCT02710669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-propafenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (S)-Propafenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00576485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery and intraocular lens implantation
Description: Cataract surgery and implantation of an intraocular lens

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery and intraocular lens implantation
Description: Cataract surgery and implantation of an intraocular lens
Study: NCT01491100

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
Study: NCT03105024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement
Description: specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
Study: NCT00714259

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation
Description: TBI 200cGy x1 dose on transplant day

Intervention type: OTHER
Group type: OTHER
Intervention: Infusion of Stem Cells
Description: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
Study: NCT02835274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSC Deep Brain Stimulation System with Directional Lead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BSC Deep Brain Stimulation System with Directional Lead
Study: NCT00872131

Intervention type: DRUG
Intervention: Sertraline
Description: Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
Study: NCT00211536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed Implantable Pump System
Description: The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aventis HOE21PH U400
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Study: NCT03164291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Study: NCT00003855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study: NCT01829529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin
Study: NCT03715127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybine oral capsule
Description: single dose of psilocybin (0.215mg / kg body weight)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: single dose of placebo (100% mannitol)
Study: NCT02735876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT04067076

Intervention type: OTHER
Intervention: Self-administered evaluation questionnaire
Description: Smartphone app with MeMind questionnaires
Study: NCT00206752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: definitive external beam radiation in the ipsilateral neck.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: definitive external beam radiation in the ipsilateral neck
Description: definitive external beam radiation in the ipsilateral neck
Study: NCT01639807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost (0.005%) eye drops, once daily in the evening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: Selective Laser Trabeculoplasty
Study: NCT00130754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobuline
Description: IV 7.5 mg/kg
Study: NCT03484884

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerenkov luminescence imaging.
Description: Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
Study: NCT02039687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer
Study: NCT03405324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study: NCT03698851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidor® and Guidor easy-graft® CRYSTAL
Description: A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidor® and Guidor easy-graft® CLASSIC
Description: Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
Study: NCT04453189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
Study: NCT05782660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Benefit
Description: Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cash Benefit
Description: No monthly cash benefit.
Study: NCT01795950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: intravenous administration of a single dose of PLX-PAD cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: intravenous administration of a single dose of PLX-PAD cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: intravenous administration of a single dose of PLX-PAD cells